Deutsche Märkte geschlossen

CureVac N.V. (5CV.DE)

XETRA - XETRA Verzögerter Preis. Währung in EUR
Zur Watchlist hinzufügen
2,8500+0,0550 (+1,97%)
Börsenschluss: 05:35PM CET

CureVac N.V.

Friedrich-Miescher-Strasse 15
Tübingen 72076
Germany
49 7071 9883 0
https://www.curevac.com

Sektor(en)Healthcare
BrancheBiotechnology
Vollzeitmitarbeiter904

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. Pierre Kemula B.Sc.MD, CFO & Member of Management Board548,92kN/A1975
Dr. Malte Greune Ph.D.COO, Member of Management Board & MD426,9kN/A1965
Dr. Ulrike Gnad-Vogt M.D., Ph.D.Senior VP & Area Head of Oncology350,5kN/A1973
Dr. Alexander Zehnder M.B.A., M.D.CEO, MD & Member of Management BoardN/AN/A1970
Dr. Myriam Mendila M.D.Chief Development Officer, MD & Member of the Management BoardN/AN/A1966
Dr. Sarah FakihVice President Corporate Communications & Investor RelationsN/AN/AN/A
Mr. Marco Rau L.L.M., Ph.D.General CounselN/AN/AN/A
Mr. Thorsten SchullerHead of Corporate CommunicationsN/AN/AN/A
Slavica Stevanovic-HeckHead of Human ResourcesN/AN/AN/A
Dr. Patrick BaumhofSenior Vice President of TechnologyN/AN/AN/A
Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer therapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Corporate Governance

CureVac N.V.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.